Preparation of a liposomal delivery system and its in vitro release of rapamycin

被引:63
作者
Miao, Zhi-Lin [1 ]
Deng, Ying-Jie [2 ]
Du, Hong-Yang [3 ]
Suo, Xu-Bin [2 ]
Wang, Xiao-Yu [2 ]
Wang, Xiao [3 ]
Wang, Li [1 ]
Cui, Li-Jie [1 ]
Duan, Na [1 ]
机构
[1] Shenyang Pharmaceut Univ, Ctr Heart, Peoples Hosp Liaoning Prov, Shenyang 110016, Liaoning, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Liaoning, Peoples R China
[3] Dalian Med Univ, Grad Sch, Dalian 116044, Liaoning, Peoples R China
关键词
atherosclerosis; rapamycin; liposomes; orthogonal design; in vitro release kinetics; reverse dialysis; targeted therapy; DRUG-DELIVERY; IMMUNOLIPOSOMES; CARDIOMYOCYTES; DESIGN; CELLS; MODEL;
D O I
10.3892/etm.2015.2201
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of this study was to prepare a liposomal delivery system for rapamycin and study its in vitro release characteristics. The results may provide a foundation for the further development of a liposomal delivery system for rapamycin and the establishment of a new active treatment method targeted towards the cellular components of atherosclerotic plaques. The ethanol injection method was used to prepare rapamycin-containing liposomes. The formulation was optimized by orthogonal design, and the degree of rapamycin release by the liposomes was measured by the reverse dialysis method. Orthogonal testing showed that the optimum formulation had a phospholipid concentration of 4%, a phospholipid-cholesterol mass ratio of 8:1, a drug-lipid mass ratio of 1:20 and an aqueous phase pH of 7.4. Rapamycin-containing liposomes with an encapsulation efficiency of 82.11 +/- 2.13% were prepared, and the in vitro release of rapamycin from the liposomes complied with a first-order kinetic equation. In conclusion, the formulation was optimized, the prepared liposomes had a high rapamycin encapsulation rate and good reproducibility, and their in vitro release had a certain delayed-release effect.
引用
收藏
页码:941 / 946
页数:6
相关论文
共 27 条
[1]   Liposomes in drug delivery: a patent review (2007-present) [J].
Arias, Jose L. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (11) :1399-1414
[2]  
Chen Y, 2005, PHARMAZIE, V60, P844
[3]  
Chen Y, 2005, PHARMAZIE, V60, P238
[4]  
Cheng-Lai Angela, 2004, Am J Ther, V11, P218, DOI 10.1097/00045391-200405000-00011
[5]   Vaccination strategies in atherosclerosis [J].
de Jager, Saskia C. A. ;
Kuiper, Johan .
THROMBOSIS AND HAEMOSTASIS, 2011, 106 (05) :796-803
[6]   Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle [J].
Gallo, R ;
Padurean, A ;
Jayaraman, T ;
Marx, S ;
Rogue, M ;
Adelman, S ;
Chesebro, J ;
Fallon, J ;
Fuster, V ;
Marks, A ;
Badimon, JJ .
CIRCULATION, 1999, 99 (16) :2164-2170
[7]   Estimation of cholesterol solubilization by a mixed micelle binding model in aqueous tauroursodeoxycholate:lecithin:cholesterol solutions [J].
Higuchi, William I. ;
Tzeng, Chinn-Shin ;
Chang, Shyh-Jye ;
Chiang, Huey-Jenn ;
Liu, Chen-Lun .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (01) :340-349
[8]  
Klugherz BD, 2000, J AM COLL CARDIOL, V35, p58A
[9]   DRUG RELEASE FROM SUBMICRONIZED O/W EMULSION - A NEW INVITRO KINETIC EVALUATION MODEL [J].
LEVY, MY ;
BENITA, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 66 (1-3) :29-37
[10]   A novel method for the preparation of liposomes: Freeze drying of monophase solutions [J].
Li, CL ;
Deng, YJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (06) :1403-1414